HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calif. ephedra bill

This article was originally published in The Tan Sheet

Executive Summary

SB 1884 (formerly SB 1750) passes state Assembly Aug. 31, has been sent to Gov. Gray Davis (D). Sponsored by Sen. Jackie Speier (D-Burlingame), bill would prohibit sale of ephedrine alkaloid supplements to minors, place more stringent warnings, FDA MedWatch number, on labeling. Davis, who vetoed similar bill in 2000, has until the end of September to sign SB 1884. In an Aug. 15 letter to FDA, Calif. Department of Health Services Director Diana Bonta, PhD, said "absent significant immediate action by the federal government to protect the public health, I intend to recommend that the governor sign this legislation" (1"The Tan Sheet" Aug. 26, 2002, p. 11)...

SB 1884 (formerly SB 1750) passes state Assembly Aug. 31, has been sent to Gov. Gray Davis (D). Sponsored by Sen. Jackie Speier (D-Burlingame), bill would prohibit sale of ephedrine alkaloid supplements to minors, place more stringent warnings, FDA MedWatch number, on labeling. Davis, who vetoed similar bill in 2000, has until the end of September to sign SB 1884. In an Aug. 15 letter to FDA, Calif. Department of Health Services Director Diana Bonta, PhD, said "absent significant immediate action by the federal government to protect the public health, I intend to recommend that the governor sign this legislation" (1 (Also see "Metabolife Proposes NIH “Blue Ribbon” Commission To Complement RAND" - Pink Sheet, 26 Aug, 2002.), p. 11)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel